December 29, 2022 10:49 AM EST
FDA+

TG cross­es the fin­ish line in MS, turn­ing U2 com­po­nent in­to stand­alone drug for biotech's sec­ond ap­proval

Paul Schloesser

Associate Editor

TG Ther­a­peu­tics fi­nal­ly got past the FDA and got a new MS drug ap­proved that the com­pa­ny plans to com­mer­cial­ize against gi­ants like Roche’s Ocre­vus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times